ArticlePediatrics2020
Parental Considerations Regarding Cure and Late Effects for Children With Cancer.
Article in Pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review.PharmacoEconomics · 2025Pooled it
- Gene Therapy-Related Malignancy and the Risk of Cancer Exceptionalism.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Parents' Distress and Demands for Children With Cancer-Related Cognitive Impairment in Western China: A Qualitative Study.Cancer medicine · 2024Article
- "A very difficult conversation": Challenges and opportunities for improvement in pediatric oncology clinician communication about late effects.Pediatric blood & cancer · 2024Article
- Severe Sepsis During Treatment for Childhood Leukemia and Sequelae Among Adult Survivors.JAMA network open · 2024Article
- The need for consensus on delineation and dose constraints of dentofacial structures in paediatric radiotherapy: Outcomes of a SIOP Europe survey.Clinical and translational radiation oncology · 2023Article
- A joint international consensus statement for measuring quality of survival for patients with childhood cancer.Nature medicine · 2023Review
- Early parental knowledge of late effect risks in children with cancer.Pediatric blood & cancer · 2022Article
- Thinking ahead: Parents' worries about late effects of childhood cancer treatment.Pediatric blood & cancer · 2021Article
- Parental decision making regarding consent to randomization on Children's Oncology Group AALL0932.Pediatric blood & cancer · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundMore than 80% of children with cancer become long-term survivors, yet most survivors experience late effects of treatment. Little is known about how parents and physicians consider late-effects risks against a potential survival benefit when making treatment decisions.
methodsWe used a discrete choice experiment to assess the importance of late effects on treatment decision-making and acceptable trade-offs between late-effects risks and survival benefit. We surveyed 95 parents of children with cancer and 41 physicians at Dana-Farber/Boston Children's Cancer and Blood Disorders Center to assess preferences for 5 late effects of treatment: neurocognitive impairment, infertility, cardiac toxicity, second malignancies, and impaired growth and development.
resultsEach late effect had a statistically significant association with treatment choice, as did survival benefit (
conclusionsAvoidance of severe neurocognitive impairment was the predominant driver of parent and physician treatment preferences, even over an increased chance of cure. This highlights the importance of exploring parental late-effects priorities when discussing treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.